Kymera Therapeutics

KYMR · Nasdaq · United States

Share price · KYMR

$121.13-0.25 (-0.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 678K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KYMR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+7.2%

    Nothing announced by KYMR that day or the session before.

  2. 30 Oct 2026+3.3%
  3. 26 Jun 2026-7.2%
  4. 25 Jun 2026+16.6%
  5. 22 Jun 2026+10.0%

    Nothing announced by KYMR that day or the session before.

  6. 2 Jun 2026-9.1%
  7. 8 Dec 2025+41.5%

Share of unusual movement by asset

For each asset, the share of KYMR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
KT-621
events and moves
926%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—36%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
STAT6Small molecule
Atopic DermatitisAsthma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
KT-621Phase 2Atopic Dermatitis
Est. primary completion 2027-06 · NCT07217015 · CT.gov ↗
What to watch
December 2027 (1)
KT-621Phase 2Eosinophilic Asthma
Est. primary completion 2027-12 · NCT07323654 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
KT-621Phase 2Asthma (Diagnosis)
Est. primary completion 2028-12 · NCT07677059 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$129M$373M+ $598M short-term inv.$132M-$78M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$65M$119M$124M+ $567M short-term inv.$61M-$54M operating cash flowreport ↗
2026-Q1$34M$98M$1.6B+ $507M short-term inv.$69M-$89M operating cash flowreport ↗
2025-Q3$2.8M$74M$113M+ $393M short-term inv.$82M-$27M operating cash flowreport ↗
2025-Q2$11M$78M$336M+ $330M short-term inv.$77M-$60M operating cash flowreport ↗
2025-Q1$22M$80M$90M+ $373M short-term inv.$66M-$79M operating cash flowreport ↗
2024-Q3$3.7M$60M$111M+ $439M short-term inv.$62M-$50M operating cash flowreport ↗
2024-Q2$26M$59M$68M+ $442M short-term inv.$42M-$43M operating cash flowreport ↗
2024-Q1$10M$49M$94M+ $427M short-term inv.$49M-$40M operating cash flowreport ↗
2023-Q3$4.7M$48M$81M+ $277M short-term inv.$53M-$32M operating cash flowreport ↗
2023-Q2$17M$46M$52M+ $315M short-term inv.$39M-$35M operating cash flowreport ↗
2023-Q1$9.5M$42M$50M+ $347M short-term inv.$41M-$44M operating cash flowreport ↗
2022-Q3$9.6M$44M$156M+ $326M short-term inv.$43M-$34M operating cash flowreport ↗
2022-Q2$12M$41M$77M+ $315M short-term inv.$40M-$39M operating cash flowreport ↗
2022-Q1$9.6M$36M$34M+ $387M short-term inv.$37M-$40M operating cash flowreport ↗
2021-Q3$20M$38M$157M+ $380M short-term inv.$29M-$37M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$39M$317M$357M+ $491M short-term inv.$78M-$233M operating cash flowreport ↗

Kymera Therapeutics reported FY2025 revenue of $39.21M, down 16.7% YoY, and R&D spend of $316.57M, up 31.8% YoY. Net loss for the year was $311.35M. The company ended the period with $357.01M in cash and equivalents and separately reported approximately $1.6 billion in cash, cash equivalents, and investments as of December 31, 2025, supporting a cash runway into 2029.

Pipeline updates included the ongoing KT-621 BROADEN2 Phase 2b trial in atopic dermatitis with data expected by mid-2027, the BREADTH Phase 2b asthma trial with data expected in late-2027, and initiation of the KT-579 Phase 1 healthy volunteer trial with data expected in 2H26. The company also received Fast Track designation for KT-621, completed a $602 million underwritten equity offering with gross proceeds of approximately $692 million, and appointed Neil Graham as Chief Development Officer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$47M$240M$120M+ $368M short-term inv.$56M-$195M operating cash flowreport ↗
2023-FY$79M$189M$110M+ $265M short-term inv.$37M-$103M operating cash flowreport ↗
2022-FY$47M$164M$68M+ $339M short-term inv.$39M-$153M operating cash flowreport ↗
2021-FY$73M$137M$48M+ $394M short-term inv.$25M-$129M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($172.5M), 274 sales ($473.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOption exercise30,000$2.08$62KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale3,525$111.44$393KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale5,506$112.42$619KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale4,876$113.24$552KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale7,601$114.43$870KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale8,230$115.40$950KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOpen-market sale262$116.12$30KForm 4
2026-10-01Mainolfi Nello · director, Chief Executive OfficerOption exercise (derivative)30,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 254 reporting institutions held 96.3M shares ($7.0B, 112.8% of shares outstanding).

#InstitutionSharesValue
1FMR LLC11,699,950$974.5M
2BAKER BROS. ADVISORS LP8,657,242$721.1M
3Avoro Capital Advisors LLC7,474,747$622.6M
4BVF INC/IL5,502,710$458.3M
5BlackRock, Inc.5,060,876$421.5M
6Atlas Venture Life Science Advisors, LLC4,578,008$381.3M
7WELLINGTON MANAGEMENT GROUP LLP3,889,687$324.0M
8Siren, L.L.C.3,186,830$265.4M
9VANGUARD CAPITAL MANAGEMENT LLC2,880,324$239.9M
10VANGUARD PORTFOLIO MANAGEMENT LLC2,874,056$239.4M
11STATE STREET CORP2,389,767$199.0M
12Capital Research Global Investors1,673,275$139.4M
13GEODE CAPITAL MANAGEMENT, LLC1,645,350$137.1M
14Driehaus Capital Management LLC1,043,583$86.9M
15UBS Group AG1,023,852$85.3M